Sponsor:
Merck Sharp & Dohme LLC
Code:
NCT06966700
Conditions
Breast Neoplasms
Triple Negative Breast Neoplasms
HR Low-Positive/HER2-Negative Breast Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab tirumotecan
Pembrolizumab
Rescue Medication
Carboplatin
Paclitaxel
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-09-11.